Literature DB >> 12582006

Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells.

Sule Sengul1, Craig Zwizinski, Vecihi Batuman.   

Abstract

We previously demonstrated that light chain (LC) endocytosis by human proximal tubule cells (PTCs) leads to production of cytokines through activation of NF-kappaB. Here, we examined the role of MAPK pathways in these responses using four species of myeloma LCs (kappa(1), kappa(2), kappa(3), and lambda(1)) previously shown to induce cytokine production by PTCs. Among these, kappa(1)-LC, which yielded the strongest cytokine responses, was selected for detailed studies. Activation of MAPKs was probed by Western blot analysis for the active kinases, ERK 1/2, JNK 1/2, and p38 in kappa(1)-LC-exposed human PTCs. To evaluate the functional role of MAPKs in LC-induced cytokine responses, we tested the effects of U-0126, an ERK inhibitor; SP-600125, an inhibitor of JNK; SB-203580, a p38 inhibitor; and curcumin, a JNK-AP-1 inhibitor, all added to media before 4-h exposure to 1.5 mg/ml kappa(1)-LC. IL-6 and monocyte chemotactic protein-1 (MCP-1) were determined by ELISA. Both LC and human serum albumin (HSA) activated ERK, although the HSA effect was weaker. kappa(1)-LC stimulated all three MAPKs, although phosphorylation of ERK was more pronounced and sustained than others. Inhibitors of ERK, JNK, and p38 reduced LC-induced IL-6 and MCP-1 production. These findings suggest that activation of MAPKs plays a role in LC-induced cytokine responses in PTCs. Activation of MAPKs may be involved in cytokine responses induced by other proteins as well as LCs and may be pivotal in the pathophysiology of tubulointerstitial injury in proteinuric diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12582006     DOI: 10.1152/ajprenal.00350.2002

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  21 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

Review 2.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.

Authors:  Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

3.  Receptor-mediated endocytosis is a Trojan horse in light-chain nephrotoxicity.

Authors:  Karl A Nath
Journal:  J Am Soc Nephrol       Date:  2010-06-17       Impact factor: 10.121

4.  Renal impairment in multiple myeloma: presenting features in different departments.

Authors:  Ni Li; Yongman Lv; Hongbing Zeng; Fan He; Ying Yao; Xiaofeng He
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

5.  Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Kristal J Aaron; Kolitha Basnayake; Paul W Sanders
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

6.  Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury.

Authors:  Wei-Zhong Ying; Xingsheng Li; Sunil Rangarajan; Wenguang Feng; Lisa M Curtis; Paul W Sanders
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

7.  Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

8.  Vasoactive intestinal peptide enhances TNF-α-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-κB-dependent mechanism.

Authors:  Ling Huang; Yiting Tang; Jiao Qin; Yu Peng; Qiongjing Yuan; Fangfang Zhang; Lijian Tao
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

9.  Serum free light chains and the risk of ESRD and death in CKD.

Authors:  Richard Haynes; Colin A Hutchison; Jonathan Emberson; Tanaji Dasgupta; David C Wheeler; John N Townend; Martin J Landray; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

Review 10.  Kidney disease and multiple myeloma.

Authors:  Eliot C Heher; Helmut G Rennke; Jacob P Laubach; Paul G Richardson
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.